Literature DB >> 24147360

New pyridocarbazole derivatives. Synthesis and their in vitro anticancer activity.

Ryszard Jasztold-Howorko1, Beata Tylińska, Bogusława Biaduń, Tomasz Gebarowski, Kazimierz Gasiorowski.   

Abstract

In this paper, we describe our results of the synthesis and biological testing of analogues of the natural alkaloids olivacine and ellipticine. We have synthesized fourteen new 1-substituted pyrido[4,3-b]carbazole derivatives. All of them were tested in vitro for their anticancer activity on three human tumor cell lines: CCRF/CEM (T lymphoblast leukemia), A549 (lung adenocarcinoma), and MCF7 (breast cancer). Cytotoxicity to non-cancer cells was estimated in cultures of the mice fibroblast cell line 3T3 BALB. The anticancer activity of 9-methoxy-5,6-dimethyl-1-[(1,1-bis-hydroxymethyI-propylamino)-methyl]-6H-pyrido[4,3-b]carbazole (compound 9) was the strongest amongst compounds tested on the three cancer cell lines; it was about 5 times higher than ellipticine and about 10% higher than doxorubicin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24147360

Source DB:  PubMed          Journal:  Acta Pol Pharm        ISSN: 0001-6837            Impact factor:   0.330


  3 in total

1.  Effect of new olivacine derivatives on p53 protein level.

Authors:  Tomasz Gębarowski; Benita Wiatrak; Katarzyna Gębczak; Beata Tylińska; Kazimierz Gąsiorowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

2.  Novel Pyrimidine Derivatives as Potential Anticancer Agents: Synthesis, Biological Evaluation and Molecular Docking Study.

Authors:  Beata Tylińska; Benita Wiatrak; Żaneta Czyżnikowska; Aneta Cieśla-Niechwiadowicz; Elżbieta Gębarowska; Anna Janicka-Kłos
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

3.  Antitumor Activity of New Olivacine Derivatives.

Authors:  Janusz Piasny; Benita Wiatrak; Agnieszka Dobosz; Beata Tylińska; Tomasz Gębarowski
Journal:  Molecules       Date:  2020-05-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.